For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,669,779 | -3,770,856.5* | 14,521,342 | 2,569,943 |
| General and administrative expenses | 2,406,587 | 2,140,941.5* | 1,287,783 | 1,353,172 |
| Total operating expenses | 5,076,366 | -1,629,915 | 15,809,125 | 3,923,115 |
| Gain from operations | -5,076,366 | 1,629,915* | -15,809,125 | -3,923,115 |
| Loss on debt conversion with related party | - | -7,078,664.75* | - | - |
| Loss on fixed asset disposal | - | -682.75* | - | - |
| Sublease income | 19,455 | - | - | - |
| Interest income (expense), net | 77,350 | -191,003.5* | 80,582 | 111,379 |
| Exchange loss, net | -5,860 | -8,450.5* | -17,509 | 4,532 |
| Total other income (expense) | 90,945 | -7,278,801.5* | 63,073 | 115,911 |
| Loss before income taxes | -4,985,421 | -5,648,886.5* | -15,746,052 | -3,807,204 |
| Deferred income tax expense | 1,193 | 223,026.5* | -1,436 | 149 |
| Net loss | -4,986,614 | -5,871,913* | -15,744,616 | -3,807,353 |
| Accrual of paid-in-kind dividends on series a non-voting convertible preferred stock | - | -314,165.5* | - | - |
| Net loss attributable to common stockholders | -4,986,614 | -6,186,078.5 | -15,744,616 | -3,807,353 |
| Basic EPS | -0.15 | -0.557 | -8.2 | -1.99 |
| Diluted EPS | -0.15 | -0.557 | -8.2 | -1.99 |
| Basic Average Shares | 33,544,748 | 11,101,777 | 1,919,433 | 1,911,128 |
| Diluted Average Shares | 33,544,748 | 11,101,777 | 1,919,433 | 1,911,128 |
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)